ABC | Volume 115, Nº1, July 2020

Original Article Pessoa et al. Cost-effectiveness comparison between drug-eluting stents and bare-metal stents Arq Bras Cardiol. 2020; 115(1):80-89 Table 4 – Outcomes at 1-year follow-up for the study groups Outcomes DES BMS p-value n % n % Bleeding 1 1.4 2 1.4 0.73 TLR 1 1.4 10 7.3 0.058 CABG 0 0 1 0.72 0.66 Angina 16 21.6 39 28.3 0.29 AMI 0 0 1 0.72 0.66 Stroke 0 0 3 2.2 0.28 ISR 1 1.4 14 10.1 0.018 New injury 1 1.4 6 4.4 0.23 Death 1 1.4 3 2.1 0.58 Categorical data were expressed as frequency (n) and percentage (%) and compared using the x 2 test or Fisher’s exact test. DES: drug-eluting stent; BMS: bare-metal stent; CABG: coronary artery bypass graft;AMI - acute myocardial infarction; CRF - chronic renal failure; ISR -  in-stent restenosis; TLR - target lesion revascularization.  Source: Author, 2018. Time of follow-up (days) Figure 2 – Event-free survival curve by stent type. E vent-free survival curve by stent type Survival without in-stent restenosis Bare-metal stent Drug-eluting stent 1.00 0.95 0.90 0.85 0.80 0.98 0.89 p=0.019 85